Diagnosis and Management of Bartter Syndrome

Diagnostic Criteria

The clinical presentation of bilateral medullary nephrocalcinosis, hypokalemia, and normal sodium/chloride levels strongly suggests Bartter syndrome, specifically type 1 or 2, which characteristically present with hypercalciuria and nephrocalcinosis 1, 2
Immediate laboratory workup should include serum electrolytes, acid-base status, plasma renin activity, aldosterone levels, and urinary calcium-creatinine ratio to confirm hypercalciuria 2, 4, 5
Genetic testing with a gene panel including SLC12A1 (type 1) and KCNJ1 (type 2) should be performed to confirm the diagnosis (grade B recommendation) 2

Sodium chloride supplementation at pharmacologic doses (5-10 mmol/kg/day) is the cornerstone of therapy (grade C recommendation) 6, 4
Potassium chloride (not potassium citrate) must be used for potassium replacement, targeting plasma potassium approximately 3.0 mmol/L 6, 4
If magnesium supplementation is needed, use organic magnesium salts (aspartate, citrate, or lactate) rather than magnesium oxide or hydroxide due to superior bioavailability, targeting plasma magnesium >0.6 mmol/l 6
NSAIDs (indomethacin) are recommended as mainstay therapy, particularly during early childhood (grade B recommendation) 6, 4
Gastric acid inhibitors must be co-administered with NSAIDs to prevent gastrointestinal complications (grade C recommendation) 6

The long-term use of NSAIDs carries risks that must be balanced against benefits, particularly regarding potential chronic kidney disease progression 1, 4
Hypokalemia in Bartter syndrome can cause life-threatening complications including paralysis, rhabdomyolysis, cardiac arrhythmias, and sudden death, and aggressive potassium replacement is essential 6
The nephrocalcinosis in Bartter syndrome types 1 and 2 typically develops after 1-2 months of life and persists despite treatment, but long-term renal function may be preserved with appropriate management 1, 2

Do not use thiazide diuretics to reduce hypercalciuria in Bartter syndrome (grade D recommendation) 6
Routine use of potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers is not recommended (grade D recommendation) 6
In patients with secondary nephrogenic diabetes insipidus, salt supplementation should be withheld (grade D recommendation) 6